Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-Pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

☰

About BioLegacy Research

Your In Vitro and In Vivo Preclinical CRO Partner from Discovery Through IND

BioLegacy Research, a San Diego-based CRO with a successful 25-year history, supports in vivo and in vitro studies across a dozen therapeutic areas. We provide sponsors with access to hundreds of animal models, and have the capacity to run studies on almost any large or small animal species used in preclinical research. We have extensive experience running non-human primate (NHP) studies. With surgical precision, intelligent study design, and expert oversight, we provide our clients with data that both sponsors and regulators can rely on. With big-CRO capabilities and small-CRO agility, BioLegacy expertly manages complex drug, device, and ATMP studies.

### Studies Completed

### Animal
Models

### Sponsors
Supported

### INDs
& IDEs

History

Facilities

Team

Values

Our History

BioLegacy Research has been delivering GLP and non-GLP preclinical research services to the pharmaceutical/biopharmaceutical, biotech, medical device, and related industries since 2001. Our history begins with the founding of Bio-Quant the Discovery Company in 2001. BTS Research was later founded in 2007 and acquired Bio-Quant in 2011. With the merging of these two companies, which continued as BTS Research, the company was able to serve sponsors for all their preclinical needs from discovery through IND-enabling studies.

BTS Research was acquired by PharmaLegacy in 2025. While it continues to operate independently, it was rebranded into BioLegacy Research. The acquisition provided a substantial investment which allowed the new BioLegacy to substantially upgrade its facilities and equipment, enabling an even greater level of service to our clients.

Facilities

BioLegacy underwent a significant facilities upgrade in 2025. Our new _____ square foot facility contains a state-of-the-art surgical suite, advanced vivariums, a new histology suite, and comprehensive bioanalytical instrumentation.

Values

Scientific Integrity

BioLegacy is passionate about science and has a deep respect for the work that it does. We appreciate the importance of the studies that our clients entrust us with. Whereas many CROs view their responsibilities as simple contractual obligations, we view our responsibility as getting the data our sponsors need to make the best decision for their pipelines. Your studies are our primary priority, not the money.

 

Accountability

Study sponsors expect their CRO partners not just to go through the motions of performing the study, but to minimize errors and problems while maximizing data integrity. To that end, everyone at BioLegacy is expected to do their best at all times. In the event a problem arises, it is expected that the team member(s) involved are transparent about it, properly identify the cause and impact of the problem, and understand what needs to be done to improve.

 

Communication

BioLegacy is open and communicative, both internally and with clients. Open communication allows us to freely share our expertise and resolve potential problems before they arise.

 

Attentiveness

BioLegacy critically analyzes its work. We do not treat studies as routine. In this way, we recognize and solve potential problems before they occur and reinforce both an individual and team sense of responsibility.

 

Advancement

Whether it pertains to advancing its clients’ pipelines, the opportunities for professional growth of its team, or the continued development of the company itself, BioLegacy always tries to move forward, continuously improve, and grow.

 

We care about your studies!

Choose BioLegacy - Start Your 
Study Now

Working with BioLegacy was a great experience. The team was very responsive and their dedication to my study was obvious. They caught a problem with our study design early on that could have resulted in serious flaws in our data, were able to suggest and execute protocol changes mid-study, and with minimal impact on cost and schedule. I would recommend BioLegacy to anyone!

Dr. FirstName LastName

Vice President of Department

Example Pharmaceuticals